Home / Expertise / Life Sciences & Healthcare / Pharmaceuticals

Pharmaceuticals

Netherlands

Pharmaceutical and healthcare law focuses on all the special legislation and legal aspects to do with medicine provision, biotechnology and healthcare. Whether it concerns manufacturing, operations, licences, rates, quality, market regulation or care insurance, there is specific legislation for all these areas.

CMS advises wholesalers, manufacturers, care institutions, professionals, sector associations and care insurers in this field.

We have extensive knowledge of the specific regulations and all other legal issues you may find yourself confronted with in this sector. For example, we can assist you in obtaining licences, biotech project financing, private initiatives in healthcare, scientific medical research, care rates and budgets, advertising and all aspects in relation to professional practice.

We also provide advice on mergers and takeovers, competition matters, tendering, patents and all kinds of contracts. You can also call on our assistance in related areas such as medical aids, healthcare products and cosmetics.

In this complex and highly regulated area of the law, both nationally and within the EU, it is vital to have access to a European network of experts. That is why we at CMS have brought together a team of specialists which allows us to be of service to you both within and far beyond our national borders.

Read more Read less
02/04/2019
WLG Can­nabis Leg­al­iz­a­tion: Europe Up­date
What is the status of can­nabis lib­er­al­iz­a­tion in the Neth­er­lands, Ger­many and Spain? Pan­el­ists El­len Gielen (CMS Neth­er­lands), Jörn Witt, Susanne Pech (both CMS Ger­many) and Juan Car­los Hernanz (Cuatreca­s­as, Spain) will give an up­date on their jur­isd
Sub­scribe to Life Sci­ences & Health­care top­ics
August 2020
CMS Life Sci­ences & Health­care Glob­al Bro­chure
With more than 300 law­yers, pat­ent at­tor­neys, sci­ent­ists and aca­dem­ics’ across CMS and the sup­port of the Life Sci­ences Asia-Pa­cific Net­work (LAN), we un­der­stand the sci­entif­ic and com­mer­cial as well as the leg­al im­per­at­ives af­fect­ing your life sci­en

Feed

Show only
02/04/2019
WLG Can­nabis Leg­al­iz­a­tion: Europe Up­date
Pod­cast
21/06/2018
El­len Gielen: "Al­tern­at­ives to ex­pens­ive medi­cines: the leg­al lee­way is...
June 2018
SYN­LAB takes con­trol with test­ing ac­quis­i­tion
An­nu­al Re­view 2017-2018
16/10/2017
Mov­ing times
Con­tinu­ity and sta­bil­ity are vi­tal when it comes to the EMA's re­lo­ca­tion when it leaves Lon­don
04/07/2016
Leg­al de­vel­op­ments in product li­ab­il­ity
With re­strict­ive le­gis­la­tion and re­cent land­mark cases, the med­ic­al in­dustry is un­der in­creas­ing leg­al pres­sure
09/10/2015
CJEU paves the way for longer SPC terms: the Seattle Ge­net­ics case
14/09/2015
Dis­tri­bu­tion and mar­ket­ing of drugs in The Neth­er­lands
06/01/2015
Changes in the Dutch Code of Con­duct for Phar­ma­ceut­ic­al Ad­vert­ising in...
18/12/2014
Tak­ing the Pulse of the Glob­al Life Sci­ences In­dustry
22/10/2013
The tricky busi­ness of drug/device clas­si­fic­a­tion in the EU
El­len Gielen and Bart Es­sink dis­cuss the im­plic­a­tions of the long-awaited court rul­ing on bor­der­line products.
14/12/2012
Dis­tri­bu­tion & mar­ket­ing of drugs : Neth­er­lands
30 May 2011
CMS ad­vises on large multi-jur­is­dic­tion­al pharma M&A trans­ac­tion